(Press-News.org) CHAPEL HILL, N.C. – A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded mixed results.
The 26-week, multicenter DURATION-6 clinical trial found that daily injections of liraglutide (Victoza) were slightly more effective than weekly injections of exenatide (Bydureon) in lowering blood sugar and promoting weight loss in patients with type 2 diabetes. However, the patients taking exenatide suffered fewer negative side effects such as nausea, diarrhea and vomiting.
"Both of these agents are very exciting diabetes products and really good blood sugar-lowering drugs," said John B. Buse, MD, PhD, first author of the study, division chief of endocrinology and metabolism in the University of North Carolina School of Medicine, director of the UNC Diabetes Care Center and a a PI Extender of the UNC NIH Clinical and Translational Science Awards (CTSA).
"The results of this study will be helpful to both doctors and patients in shared decision-making about which of these two drugs is better suited for a particular patient."
"The results of this study will be helpful to both doctors and patients in shared decision-making about which of these two drugs is better suited for a particular patient," Buse said. "For example, for some patients the additional weight loss advantage provided by liraglutide might tip the scales in favor of that drug. For other patients, though, the greater convenience of once-weekly injections and the more favorable side effects profile of exenatide would be extremely appealing."
Results of the study were published online ahead of print on Nov. 7, 2012 by The Lancet.
In the study, 912 patients from 105 sites in 19 countries were randomized to receive injections of once-daily liraglutide or once-weekly exenatide for 26 weeks. The primary endpoint of the study was the overall reduction in HbA1c (blood sugar) levels from baseline to 26 weeks.
Both drugs produced a clinically significant decrease in blood sugar levels. By the end of the study, 60 percent of the patients taking liraglutide had achieved HbA1c levels of less than 7 percent, vs. 53 percent of patients on exenatide. Both drugs also produced progressive decreases in bodyweight, but patients taking liraglutide lost about 2 pounds more weight than those on exenatide.
Patients in both groups reported having side effects on occasions over the six month trial. The most common were nausea (21 percent in the liraglutide group vs. 9 percent in the exenatide group), diarrhea (13 percent vs. 6 percent) and vomiting (11 percent vs. 4 percent). The occurrence of side effects lessened in both groups over time. Five percent of patients on liraglutide and 3 percent on exenatide dropped out of the study because of side effects.
INFORMATION:
The study was funded by Eli Lilly and Amylin Pharmaceuticals. Amylin is the manufacturer of Bydureon, the exenatide preparation that was used in this study.
In addition to Dr. Buse, other authors were Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K. Shenouda, Cory R. Heilmann, Byron J. Hoogwerf, Aijun Gao, Marilyn K. Boardman, Mark Fineman, Lisa Porter and Guntram Schemthaner.
Head-to-head trial of 2 diabetes drugs yields mixed results
2012-11-07
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Breast cancer drug could halt other tumors
2012-11-07
The drug, geldanamycin, is well known for attacking a protein associated with the spread of breast cancer. However, a laboratory-based study found it also degraded a different protein that triggers blood vessel growth.
Stopping unwanted blood vessel growth is a key challenge in the battle against cancer, according to Dr Sreenivasan Ponnambalam, reader in human disease biology in the University of Leeds' Faculty of Biological Sciences.
"This is potentially very significant because tumours secrete substances that stimulate blood vessels to develop around them, forming ...
Personalizing medicine: New American Chemical Society Prized Science video
2012-11-07
WASHINGTON, Nov. 6, 2012 — Personalized medicine — the promise of customizing treatments that will work best for each individual patient — could get a boost from advances in understanding how the proteins that help determine health and disease take the three-dimensional shapes needed to work in the body. That's the message of the latest episode of the 2012 edition of a popular video series from the American Chemical Society (ACS), the world's largest scientific society. The videos are available at www.acs.org/PrizedScience and on DVD.
Titled Prized Science: How the Science ...
New drug significantly lowers bad cholesterol
2012-11-07
BOSTON, MA—For many people with high cholesterol, statins serve as the first line of treatment. However, some patients are unable to effectively reduce their low-density lipoprotein cholesterol (LDL cholesterol) or "bad cholesterol" levels with statins, the most commonly used medication to treat high cholesterol, due to their bodies' inability to tolerate or sufficiently respond to the medicine.
Now researchers at Brigham and Women's Hospital have shown that in patients already on a statin, the addition of a new drug, called AMG 145, can reduce LDL cholesterol levels ...
Positive results from Phase 1/2 stem cell trial reported
2012-11-07
San Carlos, CA; November 6, 2012 – BioCardia, Inc., focused on regenerative biologic therapies for cardiovascular disease, today announced positive results from a Phase 1/2 heart failure trial using the Company's Helical Infusion System, comprising the Helical Infusion System Catheter™ and Morph® Vascular Access Catheter, to deliver allogeneic, or "off-the-shelf," and autologous, or from the treated patient, mesenchymal (adult) stem cells (MSCs) via transendocardial injection. According to the results, both the allogeneic and autologous MSCs were safe and well-tolerated ...
Sweet news for specialty stores: You don't need to lower prices to compete, study shows
2012-11-07
BUFFALO, N.Y. -- Specialty stores do not have to compete with supermarket prices to increase sales, according to a recent study from the University at Buffalo School of Management.
Researchers found that consumers are not concerned about higher prices when shopping at specialty stores, and that they are more likely to buy items related to their main purchase than at a supermarket.
In addition, specialty stores' customers are more apt to respond to holiday promotions than to sale prices.
The study was conducted by Ram Bezawada, PhD, assistant professor, and Minakshi ...
Virtual reality could help people lose weight, fight prejudice
2012-11-07
Internet-based interactive games and social media outlets have become intertwined with the physical realities of millions of people around the world. When an individual strongly identifies with the cyber representation of themselves, known as an avatar, the electronic doppelganger can influence that person's health and appearance, according to a University of Missouri researcher's study. Harnessing the power of the virtual world could lead to new forms of obesity treatment and help break down racial and sexual prejudices.
"The creation of an avatar allows an individual ...
'Smoke-free' laws lead to fewer hospitalizations and deaths
2012-11-07
Laws that end smoking at work and other public places result in significantly fewer hospitalizations for heart attacks, strokes, asthma and other respiratory conditions, a new UCSF analysis has found.
The research provides evidence that smoke-free laws that cover workplaces, restaurants and bars have the biggest impacts on hospitalizations, reduce health care costs and also raise quality of life, the researchers said.
The research is published in the current issue of the American Heart Association journal Circulation.
"The public, health professionals, and policy ...
Inflammation marker linked to increased risk for death from cancer in Korean men
2012-11-07
PHILADELPHIA — Measuring blood levels of high-sensitive C-reactive protein, an important marker of inflammation, in apparently cancer-free men could potentially help identify those at increased risk for death from cancer, in particular lung cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
"Inflammation has been linked to the initiation and progression of several types of cancer, as well as to the progression of atherosclerosis and cardiovascular disease," said Minseon Park, ...
Lack of vitamin D contributes to pain in black Americans with knee osteoarthritis
2012-11-07
A new study reveals that black Americans display lower levels of vitamin D and greater pain sensitivity compared to white Americans. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), indicate that vitamin D deficiency may be one of many factors that account for increased pain in older black Americans with knee osteoarthritis (OA).
Those with OA experience painful swelling and stiffness of the joints such as knees, hips and fingers. The National Arthritis Data Workgroup estimates that 27 million Americans over 25 years ...
New study finds majority of pregnant women require an average of 2 months sick leave from work
2012-11-07
Three quarters of pregnant women take sick leave from work but employers can help reduce this through flexible work adjustments, suggests a new study published today (7 November) in BJOG: An International Journal of Obstetrics and Gynaecology.
The study looked at women scheduled to give birth, at the Akershus University Hospital in Norway over an 18 month period and the prevalence of, reasons for and factors associated with sick leave during their pregnancies.
Researchers gathered information via a questionnaire conducted at week 17 and week 32 from a total of 2,918 ...